Failure to restore CD4+ cell count associated with infection-related and noninfection-related cancer.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
30
10
2021
medline:
9
4
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
To assess incidence and relative risk of cancer in Sweden, by HIV status, from 1988 to 2017. Population-based register study. From the Swedish Total Population Register, all people born between 1940 and 2000 (n = 8 587 629), and resident in Sweden sometime 1983-2017 were identified and linked to National HIV Register InfCareHIV, National Cancer Register, and LISA database. We present incidence and adjusted hazard ratios (adjHR) of infection and noninfection-related cancer for three periods between 1988 and 2017. Incidence and relative risk of infection-related cancer decreased but remained higher in people with HIV (PWH) than in HIV-negative. The proportion attributable to infection remained higher in PWH than in HIV-negative (44 vs. 9%). Women with HIV had lower risk of infection-related cancer than men with HIV [adjusted hazard ratio (adjHR) 0.6, 95% CI 0.4-0.9], mainly driven by lower incidence of Kaposi's sarcoma (adjHR 0.1, 95% CI 0.0-0.4). Current viral suppression (adjHR 0.3, 95% CI 0.2-0.5) was associated with lower risk of infection-related cancer. Current CD4+ cell count less than 200 cells/μl was associated with both infection-related (adjHR 15.3, 95% CI 10.7-21.8) and noninfection-related cancer (adjHR 2.5, 95% CI 1.5-4.1), as was CD4+ cell count increases less than 100 cells/μl post antiretroviral therapy (ART) (infection-related cancer adjHR 6.6, 95% CI 4.2-10.6, noninfection-related cancer adjHR 2.0, 95% CI 1.2-3.3). Current CD4+ cell count and failure to restore CD4+ cell count both associated with infection and noninfection-related cancer. Viral suppression associated with lower risk of infection-related cancer. Early HIV detection and early adherent ART remain essential for cancer prevention.
Identifiants
pubmed: 34711738
doi: 10.1097/QAD.0000000000003117
pii: 00002030-202203010-00014
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-457Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study . Lancet HIV 2017; 4:e495–e504.
Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States . J Natl Cancer Inst 2015; 107:dju503doi-org.proxy.kib.ki.se/10.1093/jnci/dju503.
doi: 10.1093/jnci/dju503
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis . Lancet Global health 2020; 8:e180–e190.
Biological agents. Volume 100 B. A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans. 2012. pp. 1–441.
Ruffieux Y, Muchengeti M, Egger M, Efthimiou O, Bartels L, Olago V, et al. Immunodeficiency and cancer in 3.5 million people living with human immunodeficiency virus: the South African HIV Cancer Match Study . Clin Infect Dis 2021.
Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012 . AIDS 2016; 30:1795–1806.
de Martel C, Shiels MS, Franceschi S, Simard EP, Vignat J, Hall HI, et al. Cancers attributable to infections among adults with HIV in the United States . AIDS 2015; 29:2173–2181.
Silverberg MJ, Leyden W, Hernández-Ramírez RU, Qin L, Lin H, Justice AC, et al. Timing of antiretroviral therapy initiation and risk of cancer among persons living with HIV . Clin Infect Dis 2020; 72:1900–1909.
Non-Hodgkin lymphoma risk in adults living with HIV across five continents . AIDS 2018; 32:2777–2786.
AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study . Clin Infect Dis 2017; 65:1316–1326.
Gisslen M, Svedhem V, Lindborg L, Flamholc L, Norrgren H, Wendahl S, et al. Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets . HIV Med 2016; 18:305–307.
Brannstrom J, Svedhem Johansson V, Marrone G, Wendahl S, Yilmaz A, Blaxhult A, et al. Deficiencies in the healthcare system contribute to a high rate of late HIV diagnosis in Sweden . HIV Med 2016; 17:425–435.
VanderWeele TJ. Principles of confounder selection . Eur J Epidemiol 2019; 34:211–219.
Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States . AIDS 2014; 28:881–890.
Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, et al. INSIGHT START Study Group. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection . Clin Infect Dis 2016; 63:1668–1676.
Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection . J Infect Dis 2016; 214: (Suppl 2): S44–50.
The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV . AIDS 2021; 35:747–757.
Rubin JB, Lagas JS, Broestl L, Sponagel J, Rockwell N, Rhee G, et al. Sex differences in cancer mechanisms . Biol Sex Diff 2020; 11:17.
Radkiewicz C, Johansson ALV, Dickman PW, Lambe M, Edgren G. Sex differences in cancer risk and survival: a Swedish cohort study . Eur J Cancer 2017; 84:130–140.
Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence . Eur J Epidemiol 2012; 27:187–196.
Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study . Lancet Oncol 2009; 10:1152–1159.
Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, et al. North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Association of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with kaposi sarcoma risk among HIV-infected persons in the United States and Canada . J Acquir Immune Defic Syndr 2017; 75:382–390.
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, et al. North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study . Lancet HIV 2019; 6:e240–e249.
Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J. Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents . AIDS 2013; 27:1021–1026.
de Coninck Z, Hussain-Alkhateeb L, Bratt G, Ekström AM, Gisslén M, Petzold M, et al. Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden . AIDS Patient Care STDS 2018; 32:297–305.
Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study . Ann Intern Med 2018; 169:87–96.
Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, et al. Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy . Clin Infect Dis 2014; 58:1599–1606.
Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk . Curr Opin HIV AIDS 2014; 9:34–40.
Chiao EY, Coghill A, Kizub D, Fink V, Ndlovu N, Mazul A, Sigel K. The effect of non-AIDS-defining cancers on people living with HIV . Lancet Oncol 2021; 22:e240–e253.
Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies . Curr Opin HIV AIDS 2017; 12:6–11.
Mpunga T, Znaor A, Uwizeye FR, Uwase A, Munyanshongore C, Franceschi S, et al. A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda . Int J Cancer 2018; 143:1348–1355.
Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause . AIDS 2009; 23:2337–2345.
Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study . Lancet HIV 2017; 4:e67–e73.
Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation . Physiol Rev 2020; 100:603–632.
Makinson A, Tron L, Grabar S, Milleron B, Reynes J, Le Moing V, et al. Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort . HIV Med 2020; 21:180–188.
Goedert JJ, Hosgood HD, Biggar RJ, Strickler HD, Rabkin CS. Screening for cancer in persons living with HIV infection . Trends Cancer 2016; 2:416–428.
Aboulafia DM. Cancer screening in women living with HIV infection . Women's Health (Lond) 2017; 13:68–79.
Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis . AIDS 2016; 30:273–291.